Background: Zhuoduqing formula (ZDQ) is a Chinese herbal decoction and used to treat type 2 diabetes in clinical
Introduction
Millions of people suffer from type 2 diabetes and bear a great economic burden. Currently, type 2 diabetes still has a significant increase in prevalence worldwide. It is well known that type 2 diabetes is characterized by insulin resistance. Insulin is in charge of maintaining glucose homeostasis and regulating carbohydrate, lipid metabolism through triggering insulin signaling (Saltiel and Kahn 2001) . Insulin resistance means the deficiency of insulin biological function in inducing glucose and lipid metabolism in target tissues, thus leading to metabolic disturbance, indicating chronic hyperglycemia and often accompanying with dyslipidemia including increased triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and decreased high-density lipoprotein cholesterol (HDL-c) in type 2 diabetes (Stamouli et al. 2014 ; Tian et al. 2015) . Additionally, chronic hyperglycemia and dyslipidemia, known as glucose toxicity and lipid toxicity, respectively, in turn deteriorate insulin resistance, thereby randomly assigned to two groups based on the chow diet: the NPD group and the HFD group. The rats in the former group were fed NPD, whereas the latter given HFD. After 6 weeks, the rats in the HFD group were given a single intraperitoneal injection of STZ (35 mg/kg, dissolved in freshly prepared citrate buffer), while the rats in the NPD group were injected intraperitoneally with citrate buffer. After 72 h of STZ injection, the rats whose blood glucose concentration was not less than 16.7 mmol/L were considered to have diabetes. The diabetic rats were randomly divided into the model group (MOD), the Zhuoduqing formula group (ZDQ), and the rosiglitazone group (ROS). And the rats in the NPD group were served as a control group (CON). Then, the rats were treated according to the following regimens: the Zhuoduqing formula group, receiving ZDQ (26.6 g/kg·d) by intragastric administration; the rosiglitazone group, receiving rosiglitazone (4 mg/kg·d) by oral gavage; the control and model groups, receiving an equal volume of water by oral gavage. The treatment course lasted for 4 weeks. All experimental procedures were carried out according to the guidelines of Guangxi University of Chinese Medicine for laboratory animal use and care.
Blood Glucose Assay
Blood samples of rats were collected from caudal vein by acupuncture blood. Blood glucose concentration was measured by glucose oxidase method using a portable Glucometer (Accu-Check Active, Roche Diagnostics Limited, Germany).
Insulin Sensitivity Evaluation
The homeostasis model assessment of basal insulin resistance (HOMA-IR) was used to evaluate insulin sensitivity.
The value of HOMA-IR was calculated as the following: HOMA-IR = fasting glucose × fasting insulin/22.5. This value was inversely proportional to insulin sensitivity. Additionally, intraperitoneal glucose tolerance test (IPGTT) was also used to assess insulin sensitivity.
Intraperitoneal Glucose Tolerance Tests
After 4 weeks of treatment, the rats in each group were done IPGTT. Briefly, after deprivation of food for 12-16 h, the rats were administered by intraperitoneal injection with glucose (2 g/kg). Blood samples of the rats were collected to analyze glucose concentration from caudal vein immediately (0 min), 30, 60, and 120 min after glucose injection.
The areas under the glucose curves (AUC) were evaluated according to the trapezoidal rule. Smaller AUC stands for a higher insulin sensitivity, and vice versa.
Measurement of Plasma Insulin, Fatty Profile, and TNF-α
After 4 weeks of treatment, the rats were deprived of food for 12-16 h, and then anaesthetized with pentobarbital sodium (40 mg/kg, i.p.), blood was collected from aortaventralis. Plasma was separated by centrifuge at 2000 × g for 10 minutes at 4 °C, and then used to analyze TC and TG using commercial assay kits according to manufacturer's instructions. And the levels of insulin and TNF-α were analyzed by ELISA per the manufacturer's instructions.
Measurement of SOCS-3 Levels in Skeletal Muscle Tissues
The rats were treated for 4 weeks, skeletal muscles were collected after anaesthesia with pentobarbital sodium (40 mg/kg, i.p.). The tissue was rinsed with PBS, and then homogenized in PBS. The homogenates were kept in -20°C fridge overnight. After two freeze-thaw cycles, the homogenates were centrifuged (5000 x g, 5 min, 4 °C) to remove 
Statistical Analysis
The data were analyzed with SPSS 16.0 for Windows and are presented as means ± standard error (SE). Multiple comparisons were performed using one-way analysis of variance (ANOVA) followed by LSD test. A level of P < 0.05 was regarded as statistically significant.
Results and Discussion

ZDQ Improved Insulin Resistance in Type 2 Diabetic Rats
Type 2 diabetes is characterized by chronic hyperglycemia due to worsening insulin resistance, a hallmark of type 2 diabetes. In fact, insulin resistance exists in prediabetes, thus leading to metabolic dysfunction and promoting the development of diabetes. Currently, enhancing insulin sensitivity is a key strategy for clinical treatment of type 2 diabetes. In the present study, we fed the rats HFD following intraperitoneal injection of STZ to induce type 2 diabetes, and the model rats finally showed rised fasting blood glucose ( Figure 1A ) and HOMA-IR ( Figure 1C) ; moreover, the model rats still suffered from impaired glucose tolerance, exhibiting greater AUC ( Figure 1E ) for IGPTT ( Figure 1D) compared with the control group (P < 0.01). These results indicate that the model rats had hyperglycemia and great insulin resistance which were consistent with the previous report (Cao et al. 2016) , implying the successful induction of type 2 diabetes. Therefore, we observed the effects of ZDQ on insulin resistance. Just as our clinical report (Zhao et al. 2014 ), ZDQ treatment not only significantly decreased fasting blood glucose ( Figure 1A ) in type 2 diabetic rats, but also markedly reduced HOMA-IR ( Figure 1C ), ameliorated IPGTT ( Figure 1D ), and decreased AUC ( Figure 1E ), suggesting the beneficial effects of ZDQ on type 2 diabetes. Additionally, hyperinsulinemia is indeed another characteristic of type 2 diabetes at early stage due to the compensatory elevation of insulin secretion in response to hyperglycemia. But the blood insulin level is gradually declined with the development of the disease because of the deterioration of pancreatic β cells. In this study, fasting blood insulin was decreased in type 2 diabetic rats ( Figure 1B) , which was also in according with the report (Cao et al. 2016 ). Administration of ZDQ reduced fasting blood insulin to a certain extent, implying the improvement of insulin resistance in type 2 diabetic rats in consideration of decreased fasting blood glucose and HOMA-IR by ZDQ. In clinical practice, agonists of peroxisome proliferator-activated receptors-γ (PPAR-γ) such as rosiglitazone, an insulin sensitization agent, are often utilized to treat type 2 diabetes. In this study, rosiglitazone was used as a positive control for ZDQ. As was expected, rosiglitazone lowered fasting blood glucose and improved insulin resistance, which were similar to ZDQ and strongly suggested the anti-diabetic activity of ZDQ. These results indicate that ZDQ improved insulin resistance in type 2 diabetic rats. assess insulin sensitivity of rats as materials and methods described. AUC (E) stands for areas under the glucose curves. * P < 0.05, ** P < 0.01 vs. CON; # P < 0.05, ## P < 0.01 vs. MOD. CON, control group; MOD, model group; ZDQ, Zhuoduqing formula group; ROS, rosiglitazone group. n = 5-6.
ZDQ Reduced Plasma TC and TG in Type 2 Diabetic Rats
Type 2 diabetes often associates with dyslipidemia (Tian et al. 2015) which not only increases the risk of cardiovascular disorder and initiates atherosclerosis, but also aggravates insulin resistance through inhibiting insulin signaling in insulin-targeted tissues including skeletal muscles (Park et al. 2016 ). In addition, chronic dyslipidemia causes lipid deposition and induces pancreatic lipotoxicity, thus impairing insulin secretion and promoting the progression of type 2 diabetes (Litwak et al. 2015) . In this study, both of plasma TC and TG levels were significantly increased in type 2 diabetic rats (Figure 2 ), which were agreed with the previous report (Irudayaraj et al. 2016 ). And ZDQ treatment remarkably lowered TG, and to a certain extent decreased TC. Interestingly, rosiglitazone was also confirmed to significantly reduced TC and TG levels. The past study ever showed that rosiglitazone ameliorated dyslipidemia (Cai et al. 2016) , which was in line with the results of this study. The data suggest that ZDQ improved dyslipidemia in type 2 diabetic rats in addition to anti-insulin resistant actions. Figure 2 : Effects of ZDQ on plasma TC and TG levels in type 2 diabetic rats. After 4 weeks of treatment, plasma TC and TG levels of the rats were determined. ** P < 0.01 vs. CON; # P < 0.05, ## P < 0.01 vs. MOD. CON, control group; MOD, model group; ZDQ, Zhuoduqing formula group; ROS, rosiglitazone group.
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ZDQ Decreased Plasma TNF-α Levels and SOCS-3 Levels in Skeletal Muscles of Type 2 Diabetic Rats
It is generally accepted that diabetes is an inflammatory disease. 
Conclusion
We concluded that ZDQ performs anti-diabetic functions in type 2 diabetic rats induced by feeding HFD and intraperitoneal injection of STZ.
